Stock GMED GLOBUS MEDICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Globus Medical, Inc.

Equities

GMED

US3795772082

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-19 pm EDT 		5-day change 1st Jan Change
50.35 USD -0.79% Intraday chart for Globus Medical, Inc. -2.55% -5.52%
Mar. 19 North American Morning Briefing : Stock Futures -2- DJ
Mar. 18 BTIG Upgrades Globus Medical to Buy From Neutral, Price Target is $60 MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 82% by 2026.
  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company has a low valuation given the cash flows generated by its activity.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The firm trades with high earnings multiples: 28.66 times its 2024 earnings per share.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
GLOBUS MEDICAL, INC. Stock Globus Medical, Inc.
-5.52% 6.87B
D+
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.53% 183B
C+
MEDTRONIC PLC Stock Medtronic plc
-3.52% 105B
C
DEXCOM, INC. Stock DexCom, Inc.
+5.33% 51.77B
B-
CENCORA, INC. Stock Cencora, Inc.
+16.43% 47.29B
B-
HOYA CORPORATION Stock Hoya Corporation
-1.73% 40.2B
B+
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+5.66% 27.62B
A-
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
-2.01% 25.51B
B
TERUMO CORPORATION Stock Terumo Corporation
+9.84% 24.73B
A-
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-1.87% 24.52B
B
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. GMED Stock
  4. Ratings Globus Medical, Inc.